These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30446585)

  • 1. AKT Inhibition Modulates H3K4 Demethylase Levels in PTEN-Null Prostate Cancer.
    Khan MI; Hamid A; Rath S; Ateeq B; Khan Q; Siddiqui IA; Adhami VM; Choudhry H; Zamzami MA; Mukhtar H
    Mol Cancer Ther; 2019 Feb; 18(2):356-363. PubMed ID: 30446585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.
    Li G; Kanagasabai T; Lu W; Zou MR; Zhang SM; Celada SI; Izban MG; Liu Q; Lu T; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Yan Q; Chen Z
    Cancer Res; 2020 Nov; 80(21):4633-4643. PubMed ID: 32868382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance.
    Xu W; Zhou B; Zhao X; Zhu L; Xu J; Jiang Z; Chen D; Wei Q; Han M; Feng L; Wang S; Wang X; Zhou J; Jin H
    Int J Biol Sci; 2018; 14(9):1122-1132. PubMed ID: 29989047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KDM5B focuses H3K4 methylation near promoters and enhancers during embryonic stem cell self-renewal and differentiation.
    Kidder BL; Hu G; Zhao K
    Genome Biol; 2014 Feb; 15(2):R32. PubMed ID: 24495580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone lysine demethylase KDM5B facilitates proliferation and suppresses apoptosis in human acute myeloid leukemia cells through the miR-140-3p/BCL2 axis.
    Huang J; Jin S; Guo R; Wu W; Yang C; Qin Y; Chen Q; He X; Qu J; Yang Z
    RNA; 2024 Mar; 30(4):435-447. PubMed ID: 38296629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B.
    Pippa S; Mannironi C; Licursi V; Bombardi L; Colotti G; Cundari E; Mollica A; Coluccia A; Naccarato V; La Regina G; Silvestri R; Negri R
    Molecules; 2019 May; 24(9):. PubMed ID: 31060229
    [No Abstract]   [Full Text] [Related]  

  • 7. KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma.
    Liu J; Nie C
    Anticancer Drugs; 2022 Oct; 33(9):840-849. PubMed ID: 35946516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Original Research: miR-194 inhibits proliferation and invasion and promotes apoptosis by targeting KDM5B in esophageal squamous cell carcinoma cells.
    Cui G; Liu D; Li W; Li Y; Liang Y; Shi W; Zhao S
    Exp Biol Med (Maywood); 2017 Jan; 242(1):45-52. PubMed ID: 27480251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
    BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.
    Xhabija B; Kidder BL
    Semin Cancer Biol; 2019 Aug; 57():79-85. PubMed ID: 30448242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
    Wang H; Song C; Ding Y; Pan X; Ge Z; Tan BH; Gowda C; Sachdev M; Muthusami S; Ouyang H; Lai L; Francis OL; Morris CL; Abdel-Azim H; Dorsam G; Xiang M; Payne KJ; Dovat S
    J Biol Chem; 2016 Feb; 291(8):4004-18. PubMed ID: 26655717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.
    Klein BJ; Piao L; Xi Y; Rincon-Arano H; Rothbart SB; Peng D; Wen H; Larson C; Zhang X; Zheng X; Cortazar MA; Peña PV; Mangan A; Bentley DL; Strahl BD; Groudine M; Li W; Shi X; Kutateladze TG
    Cell Rep; 2014 Jan; 6(2):325-35. PubMed ID: 24412361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. H3K4 demethylase KDM5B regulates cancer cell identity and epigenetic plasticity.
    He R; Xhabija B; Gopi LK; Kurup JT; Xu Z; Liu Z; Kidder BL
    Oncogene; 2022 May; 41(21):2958-2972. PubMed ID: 35440714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.
    Denis H; Van Grembergen O; Delatte B; Dedeurwaerder S; Putmans P; Calonne E; Rothé F; Sotiriou C; Fuks F; Deplus R
    Mol Biosyst; 2016 Feb; 12(2):404-13. PubMed ID: 26621457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
    Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
    FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylated urolithin A, the modified ellagitannin-derived metabolite, suppresses cell viability of DU145 human prostate cancer cells via targeting miR-21.
    Zhou B; Wang J; Zheng G; Qiu Z
    Food Chem Toxicol; 2016 Nov; 97():375-384. PubMed ID: 27725205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone demethylase lysine demethylase 5B in development and cancer.
    Han M; Xu W; Cheng P; Jin H; Wang X
    Oncotarget; 2017 Jan; 8(5):8980-8991. PubMed ID: 27974677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells.
    Kikuno N; Shiina H; Urakami S; Kawamoto K; Hirata H; Tanaka Y; Majid S; Igawa M; Dahiya R
    Int J Cancer; 2008 Aug; 123(3):552-60. PubMed ID: 18431742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis.
    Brown LK; Kanagasabai T; Li G; Celada SI; Rumph JT; Adunyah SE; Stewart LV; Chen Z
    Prostate; 2024 Jun; 84(9):877-887. PubMed ID: 38605532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer.
    Dhar S; Kumar A; Li K; Tzivion G; Levenson AS
    Biochim Biophys Acta; 2015 Feb; 1853(2):265-75. PubMed ID: 25447541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.